Eisai's Eisai Inc. granted Valeant exclusive, U.S. rights to develop and commercialize Targretin bexarotene

Eisai Co. Ltd.

Japan / Mid-Cap Biopharma ($1-$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Valeant Pharmaceuticals International Inc.

Canada / Mid-Cap Biopharma ($1-$50 billion)

$20,657.3m on 03/01/2013 [market cap]

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced